02 May, EOD - Indian

SENSEX 80501.99 (0.32)

Nifty 50 24346.7 (0.05)

Nifty Bank 55115.35 (0.05)

Nifty IT 35891.85 (0.27)

Nifty Midcap 100 53705.1 (-0.78)

Nifty Next 50 64429.75 (-0.12)

Nifty Pharma 21627.45 (-0.67)

Nifty Smallcap 100 16441.8 (-0.04)

02 May, EOD - Global

NIKKEI 225 36830.69 (1.04)

HANG SENG 22504.68 (1.74)

S&P 5674.27 (0.87)

LOGIN HERE

flagGufic BioSciences Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 509079 | NSE Symbol : GUFICBIO | ISIN : INE742B01025 | Industry : Pharmaceuticals |


Company History

Gufic Biosciences (GBL) was incorporated in Jul'84. The Company is a result of a reverse merger of itself with Central Finance. The promoters of GBL took over Central Finance at Rs 40-42 per share and then got GBL listed on BSE. Presently, the Company is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

The Choksi and Gandhi family, the promoters of GBL, have a long-standing presence in the pharma industry. In 1960, the family set up a joint venture company called Lyka Labs. In 1976, they decided to part ways and the Choksi family took over the manufacturing facility and the Gufic group of companies was born. Initially known as Gujarat Fine Chemicals, the first foray of the Gufic group was in the manufacture of various bulk drugs. The company later entered the formulation market. Currently, the overall profile of GBL comprises ethical products, herbal products, consumer products and bulk drugs that are sold in the domestic and the international markets.

Over the past several years, the company have a known reputation of creating brands that have vaulted to leadership positions in the category in which they have been marketed. To mention a few names: Shapers (sanitary napkins), Onergy, and Stretch nil.

In the year 2000, the company issued Bonus Equity Shares in proportion of five Equity shares for every two Equity shares held.

Gufic has divested brands in the ethical pharma business in a seller's market. The company plan to invest further in R&D activities and aggressively enter the herbal product and consumer product segments, where it foresee a huge potential. While benefiting from the rich, traditional knowledge base in India, it would like to operate from an area of strength in the herbal products segment.

In 2020-21, Gufic Lifesciences Private Limited amalgamated with the Company through the Scheme of Amalgamation which became effective from May 21, 2021. GUFIC UK LIMITED (GUL), a wholly owned subsidiary of the Company, was incorporated in United Kingdom on March 15, 2022. Similarly, in 2023, Gufic Ireland Limited (GIL) was incorporated on March 02, 2023.

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +